Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Express Scripts Holding Company Is Getting Beaten Up Today

By Cory Renauer - Apr 25, 2017 at 12:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big pharmacy benefits manager punctuated a lackluster first-quarter earnings report with the prospect of losing a major customer.

What happened

Leading pharmacy benefits manager Express Scripts Holding Company (ESRX) reported first-quarter earnings today that suggest the recent slowdown could get much worse. In response, the market shaved about 12.3% from its stock as of 12:15 p.m. EDT on Tuesday.

So what 

Express Scripts reported a 0.6% decrease in first-quarter revenue, compared to the same period last year. Successful cost-cutting efforts allowed operating profits in the quarter to rise a healthy 12.1% this year. Unfortunately, double-digit bottom-line growth couldn't detract from the likely loss of Anthem's business when its contract expires at the end 2019.

Businessperson looking very concerned.

Image source: Getty Images.

Management committed a commendable act of transparency when it announced first-quarter results after the market closed yesterday. The earnings release included a table outlining contributions from Anthem, Coventry, and Catamaran that could evaporate in the years ahead. Although Anthem is currently far and away the largest customer, the three clients contributed a combined $18.8 billion to Express Scripts' top line in 2016 or about 18.7% of total revenue reported last year.

Now what

While potential top-line losses from a falling out with Anthem, Coventry, and Catamaran are disturbing, the bottom-line implications are downright frightening. Last year, Express Scripts would have reported about 34% less in EBITDA without the trio's business.

Last year, Anthem filed a suit seeking $15 billion in damages from Express Scripts, so the eventual loss of the big insurer's business is hardly surprising. Unfortunately for Express Scripts, revealing the potential impact of a fallout with Anthem coincides with its plunge from the top spot among America's pharmacy benefit managers.

In 2016, CVS Health's PBM adjusted 1.39 billion claims, a figure that would have been larger if it had used Express Scripts' method of counting 90-day prescriptions as three 30-day scripts. By its own yardstick, Express Scripts finished the first quarter on pace to adjust about 1.41 billion claims this year.

PBMs use their size to wrangle drugmakers into providing discounts. In terms of adjusted claims, Express Scripts' degree of leverage has been flat to slightly negative lately. CVS Health's PBM, on the other hand, reported a 19.9% increase in adjusted claims last year. In an industry where being bigger attracts more clients, the potential loss of Anthem's business could eventually be more damaging than the figures published yesterday suggest.

Cory Renauer has no position in any stocks mentioned. The Motley Fool owns shares of Express Scripts. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Express Scripts Holding Company Stock Quote
Express Scripts Holding Company
Elevance Health Inc. Stock Quote
Elevance Health Inc.
$491.32 (-0.38%) $-1.90
CVS Health Corporation Stock Quote
CVS Health Corporation
$106.19 (-0.07%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.